CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc.

1:16-cv-00431

Overview

Case Number 1:16-cv-00431
Filing Date 2016-06-13
Status Terminated
Termination Date 2019-03-05
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Novartis AG Operating Company

Represented By

3 Attorneys Listed

Nicholas N. Kallas

Email: nkallas@venable.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Novartis Pharmaceuticals Corporation Operating Company

Represented By

7 Attorneys Listed

Charlotte C. Jacobsen

UNDELIVERABLE EMAIL 4/18/2022

Nicholas N. Kallas

Email: nkallas@venable.com

Jared L. Stringham

Email: jlstringham@venable.com

Christopher E. Loh

Email: cloh@venable.com

Susanne L. Flanders

Email: sflanders@venable.com

Daniel M. Silver

McCarter & English, LLP

Tel: +1 (302) 984-6300
Fax: +1 (302) 691-1260

Renaissance Centre, 405 N. King Street, 8th Floor

Benjamin A. Smyth

McCarter & English, LLP

Tel: +1 (302) 984-6300

Renaissance Centre, 405 N. King Street, 8th Floor

Plaintiff

Breckenridge Pharmaceutical Inc. Operating Company

Represented By

6 Attorneys Listed

David Ellis Moore

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Daniel R. Evans

Email: devans@merchantgould.com

Christopher J. Sorenson

Email: csorenson@merchantgould.com

Bruce J. Boggs

Email: jboggs@merchantgould.com

Selena E. Molina

Delaware Court of Chancery

Tel: +1 (302) 421-6829

Delaware Court of Chancery, 500 North King Street

Kelly E. Farnan

Richards, Layton & Finger, PA

Tel: +1 (302) 651-7705

Richards, Layton & Finger, PA, One Rodney Square

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts Counterparts in force
🏛️
USPTO PTAB Trials 9 proceedings
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): GB 🇺🇸 US 🌐 PCT
Parallel Proceedings Across Jurisdictions (9 found):
PTAB: 9
USPTO PTAB Trial 2018-01-17
IPR2018-00507

Hikma Pharmaceuticals PLC v. Novartis Pharmaceuticals Corporation

U.S. Continuation Sibling (8410131)
Status: Terminated-Settled
USPTO PTAB Trial 2017-06-12
IPR2017-01592

Breckenridge Pharmaceutial, Inc. v. Novartis Pharmaceuticals Corporation

U.S. Continuation Sibling (8410131)
Status: Terminated-Settled
USPTO PTAB Trial 2016-05-26
IPR2016-01103

Breckenridge Pharmaceutical, Inc. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Institution Denied
USPTO PTAB Trial 2016-05-26
IPR2016-01102

Roxane Laboratories, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Final Written Decision
USPTO PTAB Trial 2016-05-17
IPR2016-01059

Par Pharmaceutical, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Institution Denied
USPTO PTAB Trial 2016-05-10
IPR2016-01023

BRECKENRIDGE PHARMACEUTICAL, INC. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Final Written Decision
USPTO PTAB Trial 2015-10-26
IPR2016-00084

Par Pharmaceutical, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (5665772)
Status: Final Written Decision
USPTO PTAB Trial 2015-10-26
IPR2016-00078

Par Pharmaceutical, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (6455518)
Status: Institution Denied
USPTO PTAB Trial 2015-10-26
IPR2016-00074

Par Pharmaceutical, Inc. et al. v. Novartis AG

U.S. Continuation Sibling (7741338)
Status: Institution Denied
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

7 Patents

There are 7 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US5665772
O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Filed: 1993-09-24
Issued: 1997-09-09
Expired (Term Ended) +2176d PTA
Expires: 2019-09-09
US8410131
Cancer treatment
Filed: 2002-02-18
Issued: 2013-04-02
Expired (Term Ended) +1352d PTA
Expires: 2025-11-01
US8778962
Treatment of solid tumors with rapamycin derivatives
Filed: 2012-07-11
Issued: 2014-07-15
Active (5.6 yrs remaining)
Expires: 2032-07-11
US7297703
Macrolides
Filed: 2004-12-23
Issued: 2007-11-20
Expired (Term Ended)
Expires: 2024-12-23
US7741338
Macrolides
Filed: 2009-07-06
Issued: 2010-06-22
Active (2.6 yrs remaining)
Expires: 2029-07-06

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+2176 days) / In re Cellect scrutiny applies.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

43

Dispositive

0

Granted

2

Denied

0

Pending / Review

28

Motions by Category

Claim Construction / Markman Filing 19 Procedural / Extension Motion 20 Motion to Compel Discovery 4

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
RESPONSE to 104 MOTION for Extension of Time to Submit Joint Status Report, filed by Novartis AG, Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibi...
Entry #105 • 2019-02-21 Document →
Procedural / Extension Motion Pending / Under Review
MOTION for Extension of Time to Submit Joint Status Report - filed by Par Pharmaceutical Inc., Par Pharmaceutical Inc., Breckenridge Pharmaceutical Inc., West-W...
Entry #104 • 2019-02-20 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 80 STIPULATION and Proposed Order to Extend Time. Signed by Judge Richard G. Andrews on 4/30/2018. (nms)
Entry #— • 2018-04-30
Procedural / Extension Motion Pending / Under Review
STIPULATION and Proposed Order to Extend Time - filed by Breckenridge Pharmaceutical Inc.. (Farnan, Kelly) Modified on 4/30/2018 (nms). (Entered: 04/27/2018)
Entry #80 • 2018-04-27 Document →
Claim Construction / Markman Filing Pending / Under Review
ORAL ORDER: The Markman hearing scheduled for April 27, 2018, will be limited to one hour. Ordered by Judge Richard G. Andrews on 4/19/2018. (nms) (Entered: 04/...
Entry #78 • 2018-04-19 Document →
Claim Construction / Markman Filing Pending / Under Review
Joint Claim Construction Brief, filed by Novartis AG, Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 3/26/2018 (nms). (Entered: 03/23/2018)
Entry #76 • 2018-03-23 Document →

Docket Entries

(200 total)
Pleading / Complaint

COMPLAINT filed against Breckenridge Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1945921.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG.(Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(aah) (Attachment 1 replaced on 1/5/2017) (nms). (Entered: 06/13/2016)

Entry #1 • 2016-06-10
1
Pleading / Complaint

COMPLAINT filed against Breckenridge Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1945921.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG.(Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(aah) (Attachment 1 replaced on 1/5/2017) (nms). (Entered: 06/13/2016)

Entry #1 • 2016-06-10
2
Pleading / Complaint

COMPLAINT filed against Breckenridge Pharmaceutical Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1945921.) - filed by Novartis Pharmaceuticals Corporation, Novartis AG.(Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(aah) (Attachment 1 replaced on 1/5/2017) (nms). (Entered: 06/13/2016)

Entry #1 • 2016-06-10
2

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction.(aah) (Entered: 06/13/2016)

Entry #2 • 2016-06-10
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,665,772; 8,410,131; 8,778,962;(aah) (Entered: 06/13/2016)

Entry #3 • 2016-06-10
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc